Sign In
Buy GLYC
$15.71
+0 (+0%)
At Close: Oct 01, 2025
GLYC Stock: 62.47% Plummet Explanation
05:36am, Thursday, 16'th Feb 2023
The stock price of GlycoMimetics Inc (NASDAQ: GLYC) dropped by 62.47% in the most recent trading session. This is why.
Penny Stocks To Buy After CPI Report? 3 To Watch Today
12:10pm, Tuesday, 14'th Feb 2023
Penny stocks to watch this week. The post Penny Stocks To Buy After CPI Report?
GlycoMimetics: A Cancer-Cure Lottery Ticket Grabbing My Attention
07:40am, Tuesday, 03'rd Jan 2023
GlycoMimetics may have discovered a successful treatment for AML leukemia, currently with a 5-year survival rate of around 30%. Small research trial sizes have delivered exceptional results, with the
Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch
01:16pm, Wednesday, 28'th Dec 2022
Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?
Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?
11:17am, Friday, 02'nd Dec 2022
Here is how GlycoMimetics (GLYC) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright
11:17am, Wednesday, 23'rd Nov 2022
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
GlycoMimetics Could Surge If Q1 Data Readout Is Positive
11:22am, Friday, 11'th Nov 2022
GlycoMimetics stock price jumped on November 9. Good cancer survival results may have lengthened the timeline for a trial readout.
GlycoMimetics, Inc. (GLYC) Q3 2022 Earnings Call Transcript
11:10am, Wednesday, 09'th Nov 2022
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Christian Dinneen-Long - Company Counsel Harout Semerjian - President and Chief Exe
GlycoMimetics (GLYC) Upgraded to Buy: Here's Why
01:32pm, Tuesday, 04'th Oct 2022
GlycoMimetics (GLYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes GlycoMimetics (GLYC) a New Buy Stock
01:32pm, Tuesday, 09'th Aug 2022
GlycoMimetics (GLYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q2 2022 Results - Earnings Call Transcript
04:08pm, Wednesday, 03'rd Aug 2022
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Christian Dinneen-Long - Company Counsel Harout Semerjian - Chief Executive Officer B
GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q1 2022 Results - Earnings Call Transcript
04:52pm, Saturday, 30'th Apr 2022
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q1 2022 Results Conference Call April 28, 2022 8:30 AM ET Company Participants Shari Annes - IR Harout Semerjian - CEO Brian Hahn - CFO Armand Girard - Chief Busines
GlycoMimetics (GLYC) Q1 2022 Earnings Call Transcript
10:30pm, Thursday, 28'th Apr 2022 The Motley Fool
GLYC earnings call for the period ending March 31, 2022.
GlycoMimetics' Uproleselan: Secondary Reasons To Own The Stock
01:06pm, Wednesday, 16'th Mar 2022
Investigator-sponsored trials keep piling up.
GlycoMimetics Positive Data For AML Therapy Increasingly Likely
11:54am, Wednesday, 16'th Mar 2022
Data delay for AML therapy is most likely due to a positive OS trend.
